<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423889</url>
  </required_header>
  <id_info>
    <org_study_id>RITS13.001</org_study_id>
    <nct_id>NCT02423889</nct_id>
  </id_info>
  <brief_title>Stereotactic Volumetric Radiotherapy in Prostate Cancer</brief_title>
  <official_title>Stereotactic Radiotherapy in Low Risk Prostate Cancer: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <brief_summary>
    <textblock>
      This is a prospective, single arm, phase II, multicentric study. It evaluates the acute and
      late toxicity after stereotactic radiotherapy in low risk prostate cancer patients. All
      participants receive a total dose of 36.25 Gy in 5 fractions, twice a week, 7.25 Gy per
      fraction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>up to 3 months</time_frame>
    <description>during treatment and up to 3 month from RT end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>up to 60 months</time_frame>
    <description>since 4 month from RT end</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>up to 5 year</time_frame>
    <description>Time from treatment end to biochemical recurrence or loco-regional recurrence or metastatic disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Time from RT end to the date of patient death for cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Time from RT end to the date of patient death for any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic radiotherapy with a total dose of 36.25 Gy in 5 fractions (7.25 Gy per fraction, 2 fractions per week) in low risk prostate cancer patients is delivered to evaluate acute and subacute toxicty</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histology of prostate adenocarcinoma

          -  Age≥ 18 years

          -  Life expectancy≥ 10 years

          -  Clinical negative nodes (N0)

          -  No metastasis presence (M0)

          -  No previous pelvic radiation therapy

          -  Total PSA≤10 ng/ml

          -  Gleason score ≤ 6

          -  T1-2

          -  ≤ 3 positive biopsy at prostatic mapping

          -  Signed informed consent

        Exclusion Criteria:

          -  Positive nodes (N+) or metastatic disease (M+)

          -  Inflammatory bowel disease, collagen- vascular disorders or active autoimmune
             disorders

          -  Anticoagulant treatment in progress

          -  Hip or pelvic presence of medical devices that could prevent a correct image
             acquisition

          -  Symptomatic haemorrhoidal disease

          -  Adverse reactions to iodinate or paramagnetic contrast media

          -  Previous malignant cancer, except basocellular skin tumour or other tumours healed
             since 5 years

          -  Previous pelvic radiotherapy

          -  Psychiatric disorder that preclude to obtain informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS AOU San Martino-IST</name>
      <address>
        <city>Genoa</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Città della salute e della scienza - Molinette</name>
      <address>
        <city>Turin</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto del Radio &quot;O. Alberti&quot; Spedali Civili - University of Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</investigator_affiliation>
    <investigator_full_name>Stefano Vagge</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Hypofractionated radiotherapy</keyword>
  <keyword>SBRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

